Trial intelligence / Profile preview

Short-term versus standard-duration peginterferon alfa-2b plus ribavirin in chronic hepatitis C genotype 2 or 3 with early virologic response

2007-000279-40Phase 3Active

Sponsor
ASL 2 Savonese
Start
Mar 2007
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection (2 arms), sponsored by ASL 2 Savonese. Primary endpoints: Sustained virologic response rate, Quality of life and 1 more. Started Mar 2007; status: active.

02

Drugs

peginterferon alfa-2bribavirin
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2007-000279-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-000279-40.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call